Srolizumab is used for advanced solid tumors that are unresectable or have highly unstable metastatic microsatellites, such as advanced colorectal cancer, advanced gastric cancer, and advanced endometrial cancer. Srolizumab is a PD-1 inhibitor, clinically used for people with unresectable or metastatic microsatellite highly unstable advanced adult solid tumors, mainly used for advanced colon cancer with disease progression after treatment with fluorouracil, oxaliplatin and irinotecan, and also used for advanced gastric cancer with disease progression even after second-line treatment but without satisfactory alternative treatment options. or in patients with other advanced solid tumors who have experienced disease progression after prior first-line therapy without a satisfactory alternative treatment regimen. It has also been used in clinical trials for endometrial cancer, small bowel cancer, and breast cancer. Adverse reactions include anemia, hypertension, proteinuria, elevated aspartate aminotransferase, elevated alanine aminotransferase, lowered white blood cell count, and lowered platelet count, etc. It is contraindicated in those who are allergic to the product. If you need to use the drug, please consult your physician first.